- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| TEVOGEN Aktie jetzt für 0€ handeln | |||||
| 30.09. | Tevogen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.09. | Tevogen Inc.: Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements | 138 | GlobeNewswire (Europe) | WARREN, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. ("Tevogen" or the "Company") (Nasdaq: TVGN), an integrated healthcare enterprise combining biotechnology, artificial intelligence, and... ► Artikel lesen | |
| 18.09. | XFRA G280: WIEDERAUFNAHME/RESUMPTION | 271 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 10.09. | Tevogen Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 26.08. | Tevogen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 24.08. | Tevogen Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 30.07. | Tevogen Bio Holdings Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.07. | Tevogen Bio becomes Tevogen Inc. | 5 | Seeking Alpha | ||
| 29.07. | Tevogen Bio Holdings Inc. Becomes Tevogen Inc. | 66 | GlobeNewswire (Europe) | WARREN, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced that it will operate under the name Tevogen Inc., following approval... ► Artikel lesen | |
| 14.07. | Tevogen Bio Inc: Tevogen Bio Announces 2026 Annual Meeting of Stockholders | 1 | GlobeNewswire (USA) | ||
| 10.07. | Tevogen Bio Holdings Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 09.06. | Tevogen Bio Inc: Tevogen Announces Formation of a Healthcare Services Initiative | 689 | GlobeNewswire (Europe) | William Keane Appointed Interim Head of Initiative, Evaluating Potential Management Services Organization and Contract Research Organization Acquisitions WARREN, N.J., June 09, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| 28.05. | Tevogen Bio Inc: Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue | 753 | GlobeNewswire (Europe) | WARREN, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced continued progress across its strategic acquisition initiatives intended... ► Artikel lesen | |
| 21.05. | Tevogen Bio Inc: Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization | 579 | GlobeNewswire (Europe) | WARREN, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced that it has entered into a signed, non-exclusive, non-binding Letter... ► Artikel lesen | |
| 20.05. | Tevogen Bio Holdings reports Q1 results; operating loss falls 48% | 3 | Seeking Alpha | ||
| 18.05. | Tevogen reports reduced operating losses in 2025 and Q1 2026 | 1 | Investing.com | ||
| 18.05. | Tevogen Bio Inc: Letter to Shareholders from CEO Dr. Ryan Saadi | 233 | GlobeNewswire (Europe) | WARREN, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN). Dear Shareholders, Since Tevogen's 2024 public listing, we have remained focused on... ► Artikel lesen | |
| 15.05. | Tevogen Bio Holdings Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.05. | Tevogen Bio Inc: Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close | 389 | GlobeNewswire (Europe) | WARREN, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced that it has entered into a securities purchase agreement for a private... ► Artikel lesen | |
| 30.04. | Tevogen Bio Holdings Inc. - 10-K/A, Annual Report | - | SEC Filings |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,050 | +0,26 % | Qiagen-Aktie: Kommt jetzt das EQT-Gebot für 50 US-Dollar? | Die Qiagen-Aktie knüpft am Mittwoch vorbörslich an ihre starke Vortagsbewegung an. Auf Tradegate legte der Kurs des Dax-Titels gegenüber dem Xetra-Schluss zeitweise um bis zu 3,5% zu, zuletzt blieb... ► Artikel lesen | |
| VALNEVA | 2,331 | -0,38 % | Valneva mit ALARM: Warum unsere Experten nur eine 5- geben - Dringend vor Montag handeln! | ||
| AMGEN | 394,25 | +0,47 % | Oppenheimer reiterates Amgen stock rating on cancer drug data | ||
| NOVAVAX | 8,630 | -0,35 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 19.10.2026 | Folgende Wertpapiere werden in den Handel an der Frankfurter Wertpapierbörse (FWB) aufgenommen.
1. US88025U1097 10X GENOMICS INC
2. NL0000852564 AALBERTS NV
3. SE0016589188 ELECTROLUX AB
4. SE0000115446... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 716,90 | -0,33 % | Der große Alzheimer-Wettlauf: Wie Eisai, Novo Nordisk, Regeneron, Alnylam und NeuroThera fünf völlig verschiedene Angriffspunkte wählen | ||
| PALATIN TECHNOLOGIES | 5,110 | 0,00 % | Palatin Technologies, Inc.: Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update | Programs are focused on rare obesity disorders associated with the melanocortin 4 receptor (MC4R) pathway, including hypothalamic obesity, Prader-Willi syndrome... ► Artikel lesen | |
| OCUGEN | 0,669 | +1,36 % | SCHOCK-MELDUNG: Warum die Ocugen-Aktie von unseren Experten nur eine 5- bekommt - Das müssen Sie am Montag wissen! | ||
| INOVIO PHARMACEUTICALS | 0,844 | +5,64 % | Inovio wins case in dispute with VGXI, GeneOne Life Science | ||
| COSCIENS BIOPHARMA | 5,380 | -0,19 % | Cosciens Biopharma Inc (2): Cosciens raises $12M of up to $20M debenture deal | ||
| VIVORYON THERAPEUTICS | 0,876 | +0,69 % | Vivoryon Therapeutics N.V. Reports Outcome of 2026 Annual General Meeting | Vivoryon Therapeutics N.V. Reports Outcomeof 2026 Annual General Meeting
Halle (Saale) / Munich, Germany, September 29, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 50,62 | +1,26 % | BioMarin Pharmaceutical Inc.: BioMarin Appoints Cara Bauer as Chief People Officer | Ms. Bauer Brings More Than 25 Years of Experience in Human Resources, Across Biotechnology and Technology Industries
Appointment Effective Oct. 5, 2026
SAN RAFAEL... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 15,720 | -0,63 % | H.C. Wainwright bekräftigt Verkaufsempfehlung für Sarepta Therapeutics - Kursziel 5 US-Dollar | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,891 | +0,53 % | PacBio, Verily Health Ink Multi-Year Deal to Scale Multi-Read Genomic Data for Biomedical AI | ||
| ARROWHEAD PHARMACEUTICALS | 52,90 | +2,01 % | Biotech-Aktien vor dem Datentest: Morgan Stanley setzt auf Biotech-Moonshots: Argenx, Arrowhead, Incyte und Sana vor wichtigen Datentests | Vier Biotech-Unternehmen stehen vor wichtigen klinischen Bewährungsproben. Morgan Stanley sieht bei Argenx, Arrowhead, Incyte und Sana Programme mit hohem wirtschaftlichem Potenzial, deren weiterer... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,416 | -1,70 % | RedHill Biopharma Ltd. - 6-K, Report of foreign issuer |
TEVOGEN INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 5,775 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TEVOGEN INC finden Sie auf Wallstreet Online.